Qi Ling

Prof. Qi Ling

orcid

Research Focus & Metrics

Academic Career Length

20Years (2007-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
23 July 2022 in Nature Communications
Verified
Journal Article
Open access
PDF file
LWLiqun Wu
Liqun Wu
HYHerui Yao
Herui Yao
HCHui Chen
Hui Chen
AWAodi Wang
Aodi Wang
KGKun Guo
Kun Guo
MWminghui wang
minghui wang
Extending the benefits of tumor molecular profiling for all cancer patients requires a comprehensive analysis of tumor genomes across distinct patient populations worldwide. In this study, we perform deep next-generation DNA sequencing (NGS) from tumor tissues and matched blood specimens from over 10,000 patients in China by using a 450-gene comprehensive assay, developed and implemented under international clinical regulations. We perform a comprehensive comparison of somatically altered genes, the distribution of tumor mutational burden (TMB), gene fusion patterns, and the spectrum of various somatic alterations between Chinese and American patient populations. Here, we show 64% of cancers from Chinese patients in this study have clinically actionable genomic alterations, which may affect clinical decisions related to targeted therapy or immunotherapy. These findings describe the similarities and differences between tumors from Chinese and American patients, providing valuable information for personalized medicine.

1 October 2021 in JHEP Reports
Verified
Journal Article
Open access
RCRuihan Chen
Ruihan Chen
JDJiamin Du
Jiamin Du
HZHong Zhu
Hong Zhu
QLQi Ling
Qi Ling
The recently identified novel cytosolic DNA sensor cyclic GMP-AMP synthase (cGAS) activates the downstream adaptor protein stimulator of interferon genes (STING) by catalysing the synthesis of cyclic GMP-AMP. This in turn initiates an innate immune response through the release of various cytokines, including type I interferon. Foreign DNA (microbial infection) or endogenous DNA (nuclear or mitochondrial leakage) can serve as cGAS ligands and lead to the activation of cGAS-STING signalling. Therefore, the cGAS-STING pathway plays essential roles in infectious diseases, sterile inflammation, tumours, and autoimmune diseases. In addition, cGAS-STING signalling affects the progression of liver inflammation through other mechanisms, such as autophagy and metabolism. In this review, we summarise recent advances in our understanding of the role of cGAS-STING signalling in the innate immune modulation of different liver diseases. Furthermore, we discuss the therapeutic potential of targeting the cGAS-STING pathway in the treatment of liver diseases.

29 June 2011 in Journal of Experimental & Clinical Cancer Research
Verified
Journal Article
Open access
PDF file
QLQi Ling
Qi Ling
XXXiao Xu
Xiao Xu
XWXuyong Wei
Xuyong Wei
WWWeibing Wang
Weibing Wang
BZBin Zhou
Bin Zhou
SZShusen Zheng
Shusen Zheng
Background: Oxymatrine, an isolated extract from traditional Chinese herb Sophora Flavescens Ait, has been traditionally used for therapy of anti-hepatitis B virus, anti-inflammation and anti-anaphylaxis. The present study was to investigate the anti-cancer effect of oxymatrine on human pancreatic cancer PANC-1 cells, and its possible molecular mechanism. Methods: The effect of oxymatrine on the viability and apoptosis was examined by methyl thiazolyl tetrazolium and flow cytometry analysis. The expression of Bax, Bcl-2, Bcl-x (L/S), Bid, Bad, HIAP-1, HIAP-2, XIAP, NAIP, Livin and Survivin genes was accessed by RT-PCR. The levels of cytochrome c and caspase 3 protein were assessed by Western blotting. Results: Oxymatrine inhibited cell viability and induced apoptosis of PANC-1 cells in a time- and dose-dependent manner. This was accompanied by down-regulated expression of Livin and Survivin genes while the Bax/Bcl-2 ratio was upregulated. Furthermore, oxymatrine treatment led to the release of cytochrome c and activation of caspase-3 proteins. Conclusion: Oxymatrine can induce apoptotic cell death of human pancreatic cancer, which might be attributed to the regulation of Bcl-2 and IAP families, release of mitochondrial cytochrome c and activation of caspase-3.

18 April 2024 in American Journal of Transplantation
Verified
Journal Article
Open access
ZGZhiyong Guo
Zhiyong Guo
YLYao Liu
Yao Liu
QLQi Ling
Qi Ling
LXLeibo Xu
Leibo Xu
TWTielong Wang
Tielong Wang
XHXiaoshun He
Xiaoshun He
Immune checkpoint inhibitors (ICIs) as a downstaging or bridging therapy for liver transplantation (LT) in hepatocellular carcinoma (HCC) patients is rapidly increasing. However, the evidence about the feasibility and safety of pre-LT ICIs therapy is limited and controversial. To this end, a multicenter, retrospective cohort study was conducted in 11 Chinese centers. The results showed that 83 recipients received pre-LT ICIs therapy during the study period. The median post-LT follow up was 8.1 (interquartile range [IQR] 3.3-14.6) months. During the short follow-up, 23 (27.7%) recipients developed allograft rejection, and 7 of them (30.4%) was diagnosed by liver biopsy. Multivariate logistics regression analysis showed that time interval between the last administration of ICIs therapy and LT (TLAT) ≥ 30 days was an independent protective factor for allograft rejection (OR = 0.096, 95%CI 0.026-0.357; P < 0.001). Multivariate Cox analysis showed that allograft rejection was an independent risk factor for overall survival (OS) (HR = 9.960, 95%CI 1.006-98.610; P = 0.043). We conclude that patients who receive a pre-LT ICIs therapy with a TLAT shorter than 30 days have a much higher risk of allograft rejection than those with a TLAT longer than 30 days. The presence of rejection episodes might be associated with a higher post-LT mortality.

1 January 2024 in Theranostics
Verified
Journal Article
Open access
PDF file
XLXinqiang Li
Xinqiang Li
SLShipeng Li
Shipeng Li
YWYan Wang
Yan Wang
XZXin Zhou
Xin Zhou
FWFeng Wang
Feng Wang
JCJinzhen Cai
Jinzhen Cai
Rationale: Understanding the immune mechanisms associated with liver transplantation (LT), particularly the involvement of tissue-resident memory T cells (TRMs), represents a significant challenge.

18 January 2022 in Acta Pharmacologica Sinica
Verified
Journal Article
Closed access
PDF file
JDJia-Min Du
Jia-Min Du
MQMei-Jia Qian
Mei-Jia Qian
TYTao Yuan
Tao Yuan
RCRui-Han Chen
Rui-Han Chen
QHQiao-Jun He
Qiao-Jun He
HZHong Zhu
Hong Zhu